HANBEITAI (bevacizumab injection) was approved by the NMPA in November 2021. It is indicated for metastatic colorectal cancer (mCRC), advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, cervical cancer, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Proposed to be combined with HANSIZHUANG (PD-1) for immuno-oncology combination therapies to treat various tumors.

HANSIZHUANG (serplulimab injection, anti-PD-1 mAb), company’s first self-developed innovative monoclonal antibody, was launched in 2022. It has been approved by the NMPA for the treatment of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsNSCLC), making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. Henlius actively promotes HANSIZHUANG in conjunction with in-house products of the company and innovative therapies, and has initiated many clinical trials on immuno-oncology combination therapies worldwide, covering a wide range of indications in the fields of lung cancer and gastrointestinal tumours, etc.

In June 2021, NMPA approved Axicabtagene Ciloleucel Injection from Fosun Kairos, the first CAR-T cell product for marketing in China for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

HANLIKANG (rituximab injection) is the company's first proprietary product. It is the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guideline for the Development and Evaluation of Biosimilars (Tentative) issued in 2015. As of now, HANLIKANG has been approved by the NMPA for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis for which the originator rituximab has not been approved in China, benefiting a wider patient population with differentiated strategies.

HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac^® in Europe) was successfully launched in the U.S., China and Europe, becoming the Chinese mAb biosimilar entering the U.S., the EU and China market. It is indicated for the treatment of HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer, which corresponds to all the approved indications of the trastuzumab originator and brings more treatment options to patients with HER2 positive breast and gastric cancer worldwide.

It is the first drug approved for the treatment of thrombocytopenia associated with chronic liver diseases (CLD) in China that has been included in the National Reimbursement Drug List (NRDL) to benefit more patients! In addition, it's phase III clinical trial for the treatment of chronic immune thrombocytopenia (ITP) is ongoing.

This is category B product covered in National Reimbursement Drug List; approved by national consistency evaluation and covered in National Centralized Drug Procurement List; recommended by Chinese and global authoritative guidelines to be as first-line therapy drug for advanced hepatocellular carcinoma. Dual anti-tumor mechanism: Inhibition of tumor cell proliferation and tumor neovascularization.

The Company's first product indicated for the treatment of autoimmune diseases. HANDAYUAN (adalimumab injection) was approved by the NMPA in December 2020. It is indicated for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s disease and pediatric Crohn’s disease.

HANNAIJIA (neratinib), an orally administered small-molecule pan-HER tyrosine kinase inhibitor (TKI), was approved by NMPA in June 2024, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy. It can be used as sequential therapy after completion of HANQUYOU (trastuzumab) that is self-developed by the company to further reduce the risk of recurrence for patients with early-stage HER2-positive breast cancer.

Resolve toxin and dissipate binds, decrease swelling and relieve pain. For the syndrome of toxicity and acute blood stasis, superficial infection, dorsal furuncle swelling, multiple abscess, adenolymphitis, cold abscess

Indicated for the treatment of advanced prostate cancer in combination with luteinising hormone- releasing hormone (LHRH) analogues or surgical orchiectomy.

This is the first generic drug in China with exclusive dosage form; with triple anti-allergic mechanism to effectively treat various allergic diseases; recommended by multiple guidelines and consensuses; first-line therapy drug for allergic diseases such as urticaria, dermatitis, eczema and allergic rhinitis.

Non-small cell lung cancer (NSCLC): single is for the treatment of patients with locally advanced or metastatic NSCLC who have progressed after previous first-line chemotherapy. This product is not recommended for use in patients with histologically dominant squamous cell carcinoma. Malignant pleural mesothelioma: this product is used in combination with cisplatin to treat inoperable malignant pleural mesothelioma.